News Update

US imposes sanctions against Indian companies for supplies to RussiaPM says India heading in direction of one-nation-one-Civil CodeDeath toll in Spanish floods rises to 95BRICS + takes quantum leap but let's not rule out 'Pole-less' world in future!Mahashtra election: Cash of Rs 86 lakh recovered from car in MumbaiCBDT clarifies on CoD for returns claiming deduction u/s 80P for AY 2023-24 + specifies Forms for rollback of APA & applications u/s 35CCCCBIC revises tariff value of edible oils, gold and silverUK Budget to mop up 40 bn pound from tax hikes for wealthy BritonsVietnamese, Philippine exports to America surge for second consecutive quarter as global supply chain shiftsUN calls for probe of killings in Bangladesh protestsChina’s factory output & services perk up in Oct monthChina initiates probe against AstraZenca chief in ChinaN Korean troops to return in body bags if they enter Ukraine: USUS economy grows by 2.8% in Q3National Internet Exchange of India unveils new office at World Trade Centre, New DelhiCus - CBIC appoints adjudicators for 60 casesIndian Railways signs MoU with Switzerland's DETEC to enhance Technological Collaboration51 killed in devastating flooding in SpainGST - Circular 231 prevails over the impugned order - ITC benefit available on demo vehicles: HCIndia-China border disengagement enters into last stretchGST - Secondment of employees - IGST demand - SCNs are rendered impotent in view of Board Circular 210/4/2024 - When value of services is accepted as Nil, no further tax implication would arise: HCUN says West Asia is at ‘most dangerous juncture’ amid rising Israel-Iran mercuryGST - It is not for this Court to be boggled by or question the wisdom of the CBIC as the Circular in any case binds the respondents: HCWheeling and Dealing: The Taxing Tale of Demo VehiclesCus - CBIC releases revised list of high-end refurbished medical equipmentESIC network up from 393 Districts to 674 Districts now: Union Minister
 
GST & Customs relief to reduce MRP of 3 Anti-cancer Drugs: Govt

By TIOL News Service

NEW DELHI, OCT 30, 2024: IN line with the Government's commitment to ensure the availability of drugs at affordable prices, National Pharmaceutical Pricing Authority (NPPA) has issued an O.M. dated 28.10.2024 directing the concerned manufacturers to reduce the MRP on three anti-cancer drugs, Trastuzumab, Osimertinib and Durvalumab. This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty. The Department of Revenue, Ministry of Finance issued Notification 30/2024 dated 23.07.2024 reducing the custom duty to nil on these three anticancer drugs.

Further, the Department of Revenue, Ministry of Finance has issued notification no. 05/2024 dated 08.10.2024 notifying the reduction in GST Rates from 12% to 5% with effect from 10.10.2024 on these three drugs.

Accordingly, there should be a reduction in MRP of these drugs in the market and benefits of reduced taxes & duties should be passed on to the consumers. Hence, NPPA vide O.M. dated 28.10.2024 has directed all the manufacturers of above-mentioned drugs to reduce their MRP. The manufacturers are required to issue a price list or supplementary price list to the dealers, State Drugs Controllers and the Government indicating changes and to submit information regarding price change to NPPA through Form-II/ Form V.


POST YOUR COMMENTS
   

TIOL Tube Latest

Conferment of TIOL Awards 2024. The event was held on October 1, 2024 at Taj Palace, New Delhi



Technical Session I - Ease of Doing Business: GST on Digital Economy